YARTEMLEA

(Narsoplimab)

Phase 2Monoclonal antibody

OOmeros Corporation

YARTEMLEA is one of 19 small molecule programs targeting COVID-19. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

1 2

YARTEMLEA

OOmeros Corporation

Phase 2

1 3

Activella

Eli Lilly

Preclinical

—4

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 5

Nitrostat

VViatris Specialty LLC

Preclinical

1 6

SARS-COV-2 VACCINE

Moderna

Preclinical

2 7

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 9

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 10

Conventional

PPopulation Health Research Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 2Active, not recruiting

COVID-19

NCT04488081

Clinical

Trials by Indication[1]

Treatment1 trial

Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab

Approved for marketing·OOmeros Corporation··NCT04247906

COVID-191 trial

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active, not recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT04488081·1,500 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 23, 2025

YARTEMLEA

BLA BLA761152

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Narsoplimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Narsoplimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Narsoplimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761152). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Omeros Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: OOmeros Corporation

YARTEMLEA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Treatment1 trial

COVID-191 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News